FIFTH CIRCUIT UNANIMOUSLY RULES IN FAVOR OF INHANCE TECHNOLOGIES
Decision invalidates EPA's orders, secures continued operation of company's barrier technology facilities across the
"I am exceedingly pleased with the ruling and grateful to our customers and employees for their resilience, dedication, and support," said
In its ruling invalidating the orders, the Court agreed with Inhance Technologies that the EPA lacked the statutory authority to issue the orders.
Inhance Technologies is compliant with all applicable regulations and committed to continuing its significant research and development program to voluntarily implement measures to reduce the potential for unintentional PFAS impurity formation.
Regulatory Background
Under the Toxic Substances Control Act (TSCA), EPA may regulate a new use only if (1) the use is new (i.e., not ongoing) and (2) the new use is subject to its Significant New Use Rule (SNUR), which was never intended to cover uses that existed at the time the SNUR was proposed in 2015.
About Inhance Technologies and its Fluorination Processes
Inhance Technologies, a Responsible Care™ company, has served customers with its fluorination technology for 40 years and is committed to safe operations that are protective of its workers, local communities, the public, and the environment. Fluorinated barrier packaging is critical in protecting the environment by preventing permeation of container contents through evaporative emissions. Inhance Technologies' barrier technology annually prevents more than 25,000 metric tons of chemicals from being released into the environment that would otherwise occur due to packaging permeation. Sectors that heavily rely on Inhance Technologies' fluorination technology include crop protection, healthcare, national defense, aerospace, and fuel systems.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fifth-circuit-unanimously-rules-in-favor-of-inhance-technologies-302097343.html
SOURCE Inhance Technologies
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Franchise Academy celebrates 10 years filling franchising's biggest gap -- Business Management
- Contango Converts Remaining Hedge Contracts into Debt
- Matica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease Models
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share